ATE370970T1 - Antagonistische humane anti-hfas-ligand- antikörper und fragmente davon - Google Patents
Antagonistische humane anti-hfas-ligand- antikörper und fragmente davonInfo
- Publication number
- ATE370970T1 ATE370970T1 AT03716239T AT03716239T ATE370970T1 AT E370970 T1 ATE370970 T1 AT E370970T1 AT 03716239 T AT03716239 T AT 03716239T AT 03716239 T AT03716239 T AT 03716239T AT E370970 T1 ATE370970 T1 AT E370970T1
- Authority
- AT
- Austria
- Prior art keywords
- antibodies
- hfasl
- human antibodies
- fragments
- fas ligand
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 2
- 230000003042 antagnostic effect Effects 0.000 title 1
- 208000007654 attenuated familial adenomatous polyposis Diseases 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 3
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 abstract 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000001627 detrimental effect Effects 0.000 abstract 1
- 238000010494 dissociation reaction Methods 0.000 abstract 1
- 230000005593 dissociations Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36705402P | 2002-03-21 | 2002-03-21 | |
| US40976802P | 2002-09-10 | 2002-09-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE370970T1 true ATE370970T1 (de) | 2007-09-15 |
Family
ID=28457146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03716239T ATE370970T1 (de) | 2002-03-21 | 2003-03-12 | Antagonistische humane anti-hfas-ligand- antikörper und fragmente davon |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7262277B2 (de) |
| EP (1) | EP1490405B1 (de) |
| JP (1) | JP2005520523A (de) |
| CN (1) | CN1283662C (de) |
| AT (1) | ATE370970T1 (de) |
| AU (1) | AU2003219954B2 (de) |
| BR (1) | BR0308401A (de) |
| CA (1) | CA2478386A1 (de) |
| DE (1) | DE60315815T2 (de) |
| DK (1) | DK1490405T3 (de) |
| ES (1) | ES2291626T3 (de) |
| IL (1) | IL164011A0 (de) |
| MX (1) | MXPA04009148A (de) |
| PT (1) | PT1490405E (de) |
| WO (1) | WO2003079750A2 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| TR201809892T4 (tr) | 2003-11-05 | 2018-07-23 | Roche Glycart Ag | Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller. |
| JP4588763B2 (ja) | 2004-02-06 | 2010-12-01 | ユニバーシティー オブ マサチューセッツ | クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体およびその使用 |
| NO345919B1 (no) * | 2005-08-26 | 2021-10-18 | Roche Glycart Ag | Modifiserte antigen-bindende molekyler med endret celle-signaliseringsaktivitet |
| JP2011506371A (ja) * | 2007-12-12 | 2011-03-03 | ピンチェル ソチエタ・レスポンサビリタ・リミタータ | 抗Ｆａｓリガンド抗体を含有する天疱瘡の治療薬 |
| EP2376536B1 (de) * | 2008-12-12 | 2015-02-25 | Pincell Srl | Antikörper gegen den fas-liganden enthaltende mittel gegen pemphigus |
| US20110189194A1 (en) * | 2008-07-14 | 2011-08-04 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Use of cd95 inhibitors for the treatment of inflammatory disorders |
| CN102337298B (zh) * | 2011-08-19 | 2013-11-06 | 黄开红 | 一种输送siRNA的免疫纳米载体及其制备方法和应用 |
| JP2016508606A (ja) * | 2013-02-01 | 2016-03-22 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | トリプルネガティブ乳ガンにおける転移を予測及び予防するための方法 |
| BR112015027249A2 (pt) * | 2013-04-29 | 2017-09-26 | Apogenix Gmbh | método de diagnóstico de câncer |
| WO2015165973A1 (en) | 2014-04-29 | 2015-11-05 | Apogenix Gmbh | Diagnostic anti-cd95l antibody |
| US20220289827A1 (en) * | 2021-03-11 | 2022-09-15 | Washington University | Neutralizing antibodies to sars-cov-2 and its variants |
| WO2023138521A1 (zh) * | 2022-01-21 | 2023-07-27 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别FasL的抗体及其应用 |
| WO2023138522A1 (zh) * | 2022-01-21 | 2023-07-27 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别FasL的抗体及其应用 |
| US20250257141A1 (en) | 2022-04-26 | 2025-08-14 | Hoffmann-La Roche Inc. | Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist |
| CN121152813A (zh) * | 2023-03-23 | 2025-12-16 | 恺兴生命科技(上海)有限公司 | 细胞免疫疗法的组合物和方法 |
| KR20250164827A (ko) | 2023-03-24 | 2025-11-25 | 핀셀 에스알엘 | SJS/TEN 질환의 치료에서 항-Fas 리간드 (FasL) 항체 |
| EP4474395A1 (de) | 2023-06-06 | 2024-12-11 | PinCell S.r.l. | Antikörper gegen fas-liganden (fasl) bei der behandlung von sjs/ten-erkrankungen |
| WO2025196289A1 (en) | 2024-03-22 | 2025-09-25 | Pincell S.R.L. | New target affinity and specificity of anti sfas-l antibody, pc111 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08127594A (ja) * | 1993-11-10 | 1996-05-21 | Mochida Pharmaceut Co Ltd | Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ |
| EP0739350B1 (de) | 1994-01-07 | 2008-02-27 | Mochida Pharmaceutical Co., Ltd. | Fas-antigenbindender ligand |
| US6114507A (en) * | 1995-06-30 | 2000-09-05 | Mochida Pharmaceutical Co., Ltd. | Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody |
| US6096312A (en) * | 1995-06-30 | 2000-08-01 | Mochida Pharmaceutical Co., Ltd. | Agent for suppressing a reduction of CD4+ lymphocytes |
| CN1196733A (zh) * | 1995-06-30 | 1998-10-21 | 持田制药株式会社 | 抗Fas配体抗体和利用抗Fas配体抗体的测定方法 |
-
2003
- 2003-03-12 CN CNB038064030A patent/CN1283662C/zh not_active Expired - Fee Related
- 2003-03-12 BR BR0308401-9A patent/BR0308401A/pt not_active IP Right Cessation
- 2003-03-12 ES ES03716239T patent/ES2291626T3/es not_active Expired - Lifetime
- 2003-03-12 WO PCT/US2003/006155 patent/WO2003079750A2/en not_active Ceased
- 2003-03-12 JP JP2003577595A patent/JP2005520523A/ja active Pending
- 2003-03-12 AU AU2003219954A patent/AU2003219954B2/en not_active Ceased
- 2003-03-12 AT AT03716239T patent/ATE370970T1/de not_active IP Right Cessation
- 2003-03-12 PT PT03716239T patent/PT1490405E/pt unknown
- 2003-03-12 DK DK03716239T patent/DK1490405T3/da active
- 2003-03-12 CA CA002478386A patent/CA2478386A1/en not_active Abandoned
- 2003-03-12 MX MXPA04009148A patent/MXPA04009148A/es active IP Right Grant
- 2003-03-12 US US10/506,743 patent/US7262277B2/en not_active Expired - Fee Related
- 2003-03-12 IL IL16401103A patent/IL164011A0/xx unknown
- 2003-03-12 DE DE60315815T patent/DE60315815T2/de not_active Expired - Lifetime
- 2003-03-12 EP EP03716239A patent/EP1490405B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE60315815D1 (de) | 2007-10-04 |
| CA2478386A1 (en) | 2003-10-02 |
| PT1490405E (pt) | 2007-11-07 |
| DE60315815T2 (de) | 2008-05-21 |
| IL164011A0 (en) | 2005-12-18 |
| JP2005520523A (ja) | 2005-07-14 |
| CN1642980A (zh) | 2005-07-20 |
| CN1283662C (zh) | 2006-11-08 |
| WO2003079750A2 (en) | 2003-10-02 |
| EP1490405B1 (de) | 2007-08-22 |
| ES2291626T3 (es) | 2008-03-01 |
| EP1490405A4 (de) | 2005-09-14 |
| US20050106140A1 (en) | 2005-05-19 |
| BR0308401A (pt) | 2005-03-29 |
| AU2003219954A1 (en) | 2003-10-08 |
| EP1490405A2 (de) | 2004-12-29 |
| DK1490405T3 (da) | 2007-12-27 |
| WO2003079750A3 (en) | 2004-05-13 |
| US7262277B2 (en) | 2007-08-28 |
| MXPA04009148A (es) | 2005-02-28 |
| AU2003219954B2 (en) | 2006-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE370970T1 (de) | Antagonistische humane anti-hfas-ligand- antikörper und fragmente davon | |
| MX2009006740A (es) | Anticuerpos humanos que se unen a la il-12 humana y metodos para producirlos. | |
| TW200738749A (en) | Human antibodies that bind human IL-12 and methods for producing | |
| NO2017038I1 (no) | Adalimumab - Forlenget SPC | |
| BG111004A (bg) | Антитела, които се свързват с човешки интерлевкин-18, и методи за получаване и използване | |
| MXPA04001344A (es) | Anticuerpos humanos antagonistas contra htnfsf13b. | |
| DK1685152T3 (da) | IL-18-bindingsproteiner | |
| NO20062289L (no) | Antigen bindende molekyler med oket FC reseptor bindende affinitet og effektor funksjon | |
| EA201001528A1 (ru) | Антитела к склеростину и способы их применения | |
| WO2005016951A3 (en) | Anti-ghrelin fab antibodies | |
| MX2024006573A (es) | Anticuerpos b7-h4 y anticuerpo anti-b7-h4/ proteinas de fusion il-15. | |
| MY172707A (en) | Il-12/p40 binding proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1490405 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |